Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.

NCT Number	NCT06695585
Lead Sponsor	University of Louisville
Conditions	Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Enrollment	36 participants
Start Date	2024-12-01
Primary Completion	2025-06-01 (estimated)
Study Completion	2025-12-01 (estimated)
Updated on ClinicalTrials.gov	2024-11-19